Publications by authors named "Kata Husi"
Autologous stem cell transplantation (ASCT) is the standard treatment of primary refractory or relapsed Hodgkin-lymphoma, which can provide a cure rate of about 50%. The aim of our study was to analyze the data of 126 HL patients undergoing AHSCT in Hungary between 01/01/2016 and 31/12/2020. We assessed the progression-free and overall survival, the prognostic role of PET/CT performed before transplantation and effect of brentuximab vedotin (BV) treatment on survival outcomes.
View Article and Find Full Text PDFObjective: Although the majority of patients with Hodgkin lymphoma (HL) has recently become long-term survivors, 20%-30% of HL patients have primary refractory disease or relapse. It is essential to identify patients at risk of treatment failure during first-line therapy. To objective of the present study was to investigate the combined prognostic role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) imaging and thymus and activation-regulated chemokine (TARC) levels in Hodgkin lymphoma.
View Article and Find Full Text PDFArticle Synopsis
- * For patients who have been heavily treated and are not eligible for standard therapies, new options like Brentuximab-vedotin and combination regimens with drugs like rituximab and bendamustine show promise.
- * The study suggests that a combination of rituximab and bendamustine, potentially with Brentuximab-vedotin, could serve as a viable alternative treatment for those patients who have gone through multiple therapies.